Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D'Alessandro – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets William Wood – B. Riley Securities Operator Greetings, and welcome to the ClearPoint Neuro, Inc. First Quarter 2024 Financial Results Conference Call.

ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript

NEW YORK , May 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders.  The investigation seeks to determine whether ClearPoint Neuro's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)

Bridger Aerospace Group Holdings Inc

indie Semiconductor

iRobot

Lithium Americas Argentina Corp

Westrock Coffee Holdings LLC

Connexa Sports Technologies In

Penny stocks are on the riskier end of the public equity spectrum. They are characterized by their low volume, affordable pricing, and the rapid pace at which their values can surge or plummet compared to more traditional stocks.

7 Penny Stocks That Could Make You a Fortune (If You Dare)

ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates.

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Intuitive Surgical

Transmedics Group Inc

Many investors might overlook MedTech healthcare stocks as the next goldmine of the stock market, but these companies often demonstrate unlimited potential. Unlike their pharma counterparts, for example, MedTech healthcare stocks are often nimbler and more innovative.

The 3 Most Promising MedTech Stocks to Invest In Now

ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick

SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner PTC Therapeutics on completion of its BLA submission to the U.S. Food and Drug Administration (FDA) for the approval of Upstaza™ (eladocagene exuparvovec), an investigational treatment for AADC Deficiency.

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago.

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2023.

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.

ClearPoint's (CLPT) Prism System Favored by Latest Study

Aehr Test Systems

Hanesbrands

Nintendo

Rocket Lab USA

Steelcase

Sirius XM Holdings Inc

Fifteen bucks won't go too far these days – unless you want to invest in these under-$15 stocks to buy. Inflation growth may be falling, which obscures the real fact that pricing today for goods and services remains higher than just two years ago.

The Top 7 Under-$15 Stocks to Buy in March 2024

SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares of its common stock at a price to the public of $6.50 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 346,154 shares of its common stock at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on March 4, 2024, subject to customary closing conditions.

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

AST SpaceMobile

SoundHound AI Inc

Finding a quality up-and-coming stock is a tricky proposition, but doubly so now that we're well past the ZIRP-era “stocks go up” sentiment. In the past, you could throw capital at any up-and-coming stock and have a pretty good chance of generating returns.

The 3 Up-and-Coming Stocks That Could Make Your February Unforgettable

Charles River Laboratories

Evotec SE

Johnson & Johnson (NYSE: JNJ ) is one of the all-time great blue chip growth and income investments. JNJ stock has rallied approximately 7,000% over the past 40 years, and that figure doesn't even factor in dividends.

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn't Ignore.

ClearPoint Neuro's stock has performed well over the past 4 months, supported by solid business fundamentals. Despite the move higher, ClearPoint's valuation is still modest, given the company's potential. The progression of therapies through clinical trials, along with the rollout of its laser therapy system and operating room system, should drive solid growth in 2024.

ClearPoint Neuro: Potential Inflection Point

Vertex Pharmaceuticals

Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can generally afford more than the bare minimum of care.

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

Hims & Hers Health

Small-cap healthcare stocks might be the next stock market goldmine, but many investors are overlooking the sector's potential. Small-cap healthcare stocks tend to be nimbler and more innovative than their blue-chip counterparts (with some exceptions), meaning they're better equipped to navigate tricky market conditions and changing industry trends.

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024

SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced installation and completion of an initial procedure with both the ClearPoint Prism Neuro Laser Therapy System and the ClearPoint Neuro Navigation System by Dr. Jonathan Riley and team at Kaleida Health in Buffalo, New York.

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

News for Clearpoint Neuro Inc Stock (CLPT)